^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

DDP-38003

i
Other names: DDP-38003
Associations
Trials
Company:
Rasna Therap
Drug class:
LSD1 inhibitor
Associations
Trials
over2years
Pharmacological inhibition of LSD1 triggers myeloid differentiation by targeting GSE1 oncogenic functions in AML. (PubMed, Oncogene)
Here, we unraveled a novel mode of action of the LSD1 inhibitors MC2580 and DDP-38003, showing that they can induce differentiation of AML cells through the downregulation of the chromatin protein GSE1...Moreover, we show that LSD1 inhibitors lead to the reduced binding of GSE1 to these promoters, activating transcriptional programs that trigger myeloid differentiation. Our study offers new insights into GSE1 as a novel therapeutic target for AML.
Journal
|
KDM1A (Lysine Demethylase 1A) • GSE1 (Gse1 Coiled-Coil Protein)
|
KDM1A overexpression • KDM1A expression
|
DDP-38003